Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11520209,IC(50),"A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats.",Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11520209/),nM,8,12656,DB00244,Mesalazine
,11520209,ID(50),"A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats.",Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11520209/),[μg] / [kg],29,12657,DB00244,Mesalazine
,3557190,distribution half-life,After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min.,Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),min,17,12912,DB00244,Mesalazine
,3557190,elimination half-life,After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min.,Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),min,42,12913,DB00244,Mesalazine
,3557190,Bioavailabilities,"Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,19,12914,DB00244,Mesalazine
,3557190,Bioavailabilities,"Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,75,12915,DB00244,Mesalazine
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,78,12916,DB00244,Mesalazine
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,52,12917,DB00244,Mesalazine
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,55,12918,DB00244,Mesalazine
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,21,12919,DB00244,Mesalazine
,18691952,flow rate,Plasma samples were analyzed after protein precipitation with methanol and the two analytes were separated using a C18 column with a mobile phase composed of 17.5 mmol/L acetic acid (pH 3.3):acetonitrile=85:15 (v/v) at 0.2 mL/min flow rate.,Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),[ml] / [min],0.2,14661,DB00244,Mesalazine
,18691952,m/,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,152,14662,DB00244,Mesalazine
,18691952,m/,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,108,14663,DB00244,Mesalazine
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,194,14664,DB00244,Mesalazine
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,150,14665,DB00244,Mesalazine
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,194,14666,DB00244,Mesalazine
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,107,14667,DB00244,Mesalazine
>,18691952,overall recoveries,"The overall recoveries (n=6) at three tested concentration levels (i.e. 100, 1000 and 4000 ng/mL) were respectively >90% for 5-ASA and >95% for N-Ac-5-ASA (R.S.D.% < or = 10%).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),%,90,14668,DB00244,Mesalazine
>,18691952,overall recoveries,"The overall recoveries (n=6) at three tested concentration levels (i.e. 100, 1000 and 4000 ng/mL) were respectively >90% for 5-ASA and >95% for N-Ac-5-ASA (R.S.D.% < or = 10%).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),%,95,14669,DB00244,Mesalazine
< or =,18691952,overall recoveries,"The overall recoveries (n=6) at three tested concentration levels (i.e. 100, 1000 and 4000 ng/mL) were respectively >90% for 5-ASA and >95% for N-Ac-5-ASA (R.S.D.% < or = 10%).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),%,10,14670,DB00244,Mesalazine
,18691952,maximum concentration,The mean maximum concentration levels were 680 ng/mL for 5-ASA and 1240 ng/mL for N-Ac-5-ASA and the kinetic profiles were in agreement with previous studies.,Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),[ng] / [ml],680,14671,DB00244,Mesalazine
,18691952,maximum concentration,The mean maximum concentration levels were 680 ng/mL for 5-ASA and 1240 ng/mL for N-Ac-5-ASA and the kinetic profiles were in agreement with previous studies.,Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),[ng] / [ml],1240,14672,DB00244,Mesalazine
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],3. 9,24479,DB00244,Mesalazine
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],15.4,24480,DB00244,Mesalazine
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],46.8,24481,DB00244,Mesalazine
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],17.2,24482,DB00244,Mesalazine
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],30. 9,24483,DB00244,Mesalazine
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],57.8,24484,DB00244,Mesalazine
,10759687,urinary excretion,"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),mg,250,24485,DB00244,Mesalazine
,10759687,urinary excretion,"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),mg,52,24486,DB00244,Mesalazine
,10759687,urinary excretion,"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),mg,146,24487,DB00244,Mesalazine
,2034991,faecal water concentration,The faecal water concentration of mesalazine was significantly higher after suppository treatment (55.7 mmol/l) compared with enema treatment (31.7 mmol/l) (p less than 0.01).,Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034991/),[mM] / [l],55.7,27153,DB00244,Mesalazine
,2034991,faecal water concentration,The faecal water concentration of mesalazine was significantly higher after suppository treatment (55.7 mmol/l) compared with enema treatment (31.7 mmol/l) (p less than 0.01).,Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034991/),[mM] / [l],31.7,27154,DB00244,Mesalazine
,31056855,maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),[ng] / [ml],2084,32858,DB00244,Mesalazine
,31056855,maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),[ng] / [ml],2409,32859,DB00244,Mesalazine
,31056855,time to reach the maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),h,11,32860,DB00244,Mesalazine
,31056855,time to reach the maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),[ng] / [ml],2409,32861,DB00244,Mesalazine
,31056855,time to reach the maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),h,9,32862,DB00244,Mesalazine
,16466733,flow rate,The whole analysis lasted 23 min at the flow rate of 1 ml min(-1).,High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16466733/),[ml] / [min],1,35576,DB00244,Mesalazine
,16466733,LLOQ (LOD),LLOQ (LOD) was estimated 126 (20) pmol ml(-1) of plasma for N-acetyl-5-ASA and 318 (50) pmol ml(-1) of plasma for N-propionyl-5-ASA.,High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16466733/),[pM] / [ml],126,35577,DB00244,Mesalazine
,16466733,LLOQ (LOD),LLOQ (LOD) was estimated 126 (20) pmol ml(-1) of plasma for N-acetyl-5-ASA and 318 (50) pmol ml(-1) of plasma for N-propionyl-5-ASA.,High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16466733/),[pM] / [ml],318,35578,DB00244,Mesalazine
,9169983,time when,"After the oral administration of SASP at the does of 25.0 mg/kg, the mean time when the plasma 5-ASA concentration reaches to its maximum (Tmax) was 9.0 hr.",Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169983/),h,9.0,38801,DB00244,Mesalazine
,9169983,Tmaxs,"In the case of 5-ASA administered in PCC, at the doses of 12.5 and 25.0 mg/kg, Tmaxs were 5.3 and 5.3 hr, respectively.",Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169983/),h,5.3,38802,DB00244,Mesalazine
,15142198,total,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.26,54223,DB00244,Mesalazine
,15142198,urinary excretion,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.26,54224,DB00244,Mesalazine
,15142198,urinary excretion,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.31,54225,DB00244,Mesalazine
,15142198,A(e)%,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.26,54226,DB00244,Mesalazine
,15142198,A(e)%,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.31,54227,DB00244,Mesalazine
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,0.39,54228,DB00244,Mesalazine
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,0.37,54229,DB00244,Mesalazine
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,18.78,54230,DB00244,Mesalazine
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,18.83,54231,DB00244,Mesalazine
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],3295,54232,DB00244,Mesalazine
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],3449,54233,DB00244,Mesalazine
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],15 364,54234,DB00244,Mesalazine
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],16 050,54235,DB00244,Mesalazine
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],319,54236,DB00244,Mesalazine
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],348,54237,DB00244,Mesalazine
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],927,54238,DB00244,Mesalazine
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],1009,54239,DB00244,Mesalazine
,21251889,total run time,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,9.0,59775,DB00244,Mesalazine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,4.8,59776,DB00244,Mesalazine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.5,59777,DB00244,Mesalazine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.0,59778,DB00244,Mesalazine
,8104772,local bioavailability,"The local bioavailability in the distal gut lumen, reflected by the 5-aminosalicylic acid concentration in the fecal water, showed comparable values after Pentasa (4.44 mmol/liter) and Salazopyrin (6.25 mmol/liter).",Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),[mM] / [l],4.44,72014,DB00244,Mesalazine
,8104772,local bioavailability,"The local bioavailability in the distal gut lumen, reflected by the 5-aminosalicylic acid concentration in the fecal water, showed comparable values after Pentasa (4.44 mmol/liter) and Salazopyrin (6.25 mmol/liter).",Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),[mM] / [l],6.25,72015,DB00244,Mesalazine
,8104772,urinary excretion,The urinary excretion of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid was higher after Pentasa than after Salazopyrin (32% vs 25%).,Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),%,32,72016,DB00244,Mesalazine
,8104772,urinary excretion,The urinary excretion of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid was higher after Pentasa than after Salazopyrin (32% vs 25%).,Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),%,25,72017,DB00244,Mesalazine
,2877884,24-hour recoveries,"The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively.",5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,90.5,80941,DB00244,Mesalazine
,2877884,24-hour recoveries,"The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively.",5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,84.7,80942,DB00244,Mesalazine
,2877884,release,The median release of 5-ASA from SASP was 50% and from Pentasa 75%.,5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,50,80943,DB00244,Mesalazine
,2877884,release,The median release of 5-ASA from SASP was 50% and from Pentasa 75%.,5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,75,80944,DB00244,Mesalazine
,26541989,relative absorption,"In pharmacokinetic studies, the mean relative absorption of budesonide in the region between the ascending colon and the descending/sigmoid colon was 95.9 %.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),%,95.9,82651,DB00244,Mesalazine
,26541989,time,"A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),year,>,82652,DB00244,Mesalazine
,26541989,time,"A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),year,1,82653,DB00244,Mesalazine
,26541989,time,"A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),d,181,82654,DB00244,Mesalazine
,1748043,plasma half-life,"Following intravenous administration, the drug was rapidly eliminated with a plasma half-life of about 40 min, mainly due to rapid metabolism.",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),min,40,91724,DB00244,Mesalazine
,1748043,total recovery,"No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%).",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),%,30,91725,DB00244,Mesalazine
,1748043,total recovery,"No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%).",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),%,77,91726,DB00244,Mesalazine
,1748043,total recovery,"No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%).",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),%,72,91727,DB00244,Mesalazine
,7117789,steady state plasma acetyl-5-aminosalicylic acid concentration,Fourteen healthy volunteers took 1500 mg of 5-aminosalicylic acid per day for 6 days and a steady state plasma acetyl-5-aminosalicylic acid concentration was reached on day 5 (1.1-2.9 microgram/ml).,"5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117789/),[μg] / [ml],1.1-2.9,93162,DB00244,Mesalazine
,4039590,elimination half-life (t 1/2),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),h,0.7 to 2.4,104650,DB00244,Mesalazine
,4039590,elimination half-life (t 1/2),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),h,1.4,104651,DB00244,Mesalazine
,4039590,steady-state plasma levels (Css),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],0.7,104652,DB00244,Mesalazine
,4039590,steady-state plasma levels (Css),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],1.2,104653,DB00244,Mesalazine
,4039590,t 1/2,"Treatment with the smaller dose of 0.25 g 5-AS tid (n = 5) resulted in a shorter t 1/2 (0.6 +/- 0.2 h), lower Css for 5-AS (0.4 +/- 0.2 micrograms/ml) and Ac-5-AS (1.0 +/- 0.2 micrograms/ml).",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),h,0.6,104654,DB00244,Mesalazine
,4039590,Css,"Treatment with the smaller dose of 0.25 g 5-AS tid (n = 5) resulted in a shorter t 1/2 (0.6 +/- 0.2 h), lower Css for 5-AS (0.4 +/- 0.2 micrograms/ml) and Ac-5-AS (1.0 +/- 0.2 micrograms/ml).",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],0.4,104655,DB00244,Mesalazine
,4039590,Css,"Treatment with the smaller dose of 0.25 g 5-AS tid (n = 5) resulted in a shorter t 1/2 (0.6 +/- 0.2 h), lower Css for 5-AS (0.4 +/- 0.2 micrograms/ml) and Ac-5-AS (1.0 +/- 0.2 micrograms/ml).",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],1.0,104656,DB00244,Mesalazine
,4039590,Urinary,"Urinary and fecal recovery of total 5-AS was calculated to 44 +/- 21% and 35 +/- 10%, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),%,44,104657,DB00244,Mesalazine
,4039590,f,"Urinary and fecal recovery of total 5-AS was calculated to 44 +/- 21% and 35 +/- 10%, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),%,44,104658,DB00244,Mesalazine
,4039590,f,"Urinary and fecal recovery of total 5-AS was calculated to 44 +/- 21% and 35 +/- 10%, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),%,35,104659,DB00244,Mesalazine
,8141827,AUC,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[ug] / [h·ml],6,115988,DB00244,Mesalazine
,8141827,Cmax,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[μg] / [ml],1.7,115989,DB00244,Mesalazine
,8141827,tmax,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),h,5,115990,DB00244,Mesalazine
,8141827,Cminss,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[μg] / [ml],0.5,115991,DB00244,Mesalazine
,8141827,Cavss,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[μg] / [ml],0.75,115992,DB00244,Mesalazine
,8141827,t1/2,Following the delayed absorption 5-ASA was rapidly eliminated (t1/2 = 1.4 +/- 0.5 h).,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),h,1.4,115993,DB00244,Mesalazine
,17576207,relative bioavailability,"First, systemic exposure to 5-ASA was markedly lower after rectal drug administration as compared to oral dosing (P < 0.001; e.g. median relative bioavailability of 60 mL rectal foam: 36%).",A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576207/),%,36,131529,DB00244,Mesalazine
,17576207,area under the curve (AUC) ratio,"Second, N-acetylation of rectal 5-ASA was lower in patients than in healthy subjects [area under the curve (AUC) ratio Ac-5-ASA/5-ASA: 1.6 +/- 0.5 vs. 2.3 +/- 0.4, mean +/- SD, P < 0.01].",A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576207/),,1.6,131530,DB00244,Mesalazine
,17576207,area under the curve (AUC) ratio,"Second, N-acetylation of rectal 5-ASA was lower in patients than in healthy subjects [area under the curve (AUC) ratio Ac-5-ASA/5-ASA: 1.6 +/- 0.5 vs. 2.3 +/- 0.4, mean +/- SD, P < 0.01].",A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576207/),,2.3,131531,DB00244,Mesalazine
,2565380,steady state plasma level,Range of variable steady state plasma level of 5-ASA was 0.1-5 mg/L and of its acetyl-metabolite (Ac-5-ASA) was 1-8 mg/L.,Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565380/),[mg] / [l],0.1-5,134318,DB00244,Mesalazine
,2565380,steady state plasma level,Range of variable steady state plasma level of 5-ASA was 0.1-5 mg/L and of its acetyl-metabolite (Ac-5-ASA) was 1-8 mg/L.,Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565380/),[mg] / [l],1-8,134319,DB00244,Mesalazine
,2059673,AUC,"Within and between subject variability estimates for AUC of ac-5-ASA were 24 per cent and 46 per cent, respectively.",Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2059673/),%,24,134430,DB00244,Mesalazine
,2059673,AUC,"Within and between subject variability estimates for AUC of ac-5-ASA were 24 per cent and 46 per cent, respectively.",Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2059673/),%,46,134431,DB00244,Mesalazine
,2353171,Peak mean concentrations,"Peak mean concentrations of mesalazine and its main metabolite, Ac-5-ASA, were 0.5 microgram/ml and 1.0 microgram/ml, respectively, and occurred 3 to 4 h after gastric emptying.",Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2353171/),[μg] / [ml],0.5,138183,DB00244,Mesalazine
,2353171,Peak mean concentrations,"Peak mean concentrations of mesalazine and its main metabolite, Ac-5-ASA, were 0.5 microgram/ml and 1.0 microgram/ml, respectively, and occurred 3 to 4 h after gastric emptying.",Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2353171/),[μg] / [ml],1.0,138184,DB00244,Mesalazine
,2864155,elimination half-life,Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process.,"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139123,DB00244,Mesalazine
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,14,139124,DB00244,Mesalazine
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,6,139125,DB00244,Mesalazine
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],40,139126,DB00244,Mesalazine
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],150,139127,DB00244,Mesalazine
,2864155,elimination half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,0.5 to 1.5,139128,DB00244,Mesalazine
,2864155,half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139129,DB00244,Mesalazine
less,2864155,steady-state plasma concentrations,"During therapy with sulphasalazine or 5-ASA, steady-state plasma concentrations of 5-ASA are relatively low (less than or equal to 2 micrograms/ml); thus its mode of action appears to be topically rather than systemically.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[μg] / [ml],2,139130,DB00244,Mesalazine
,27382255,particle diameters,The mean particle diameters of mesalamine-coated microparticles were 312.2 µm.,A novel pH-enzyme-dependent mesalamine colon-specific delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27382255/),µm,312.2,142881,DB00244,Mesalazine
,2129640,urinary excretion,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,5.2,144701,DB00244,Mesalazine
,2129640,urinary excretion,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,27.9,144702,DB00244,Mesalazine
,2129640,urinary excretion,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,23.0,144703,DB00244,Mesalazine
,2129640,concentration,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),[mM] / [l],0.8,144704,DB00244,Mesalazine
,2129640,release,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),[mM] / [l],2.4,144705,DB00244,Mesalazine
,2129640,release,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),mm,5.5,144706,DB00244,Mesalazine
,2129640,urinary excretion,"This can be explained by a larger systemic absorption of 5-ASA from Claversal, and accordingly Claversal treatment resulted in the largest urinary excretion of 5-ASA and Ac-5-ASA (43.7% vs Asacol 35.6% and Pentasa 31.6%, median values of ingested daily dose).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,43.7,144707,DB00244,Mesalazine
,2129640,urinary excretion,"This can be explained by a larger systemic absorption of 5-ASA from Claversal, and accordingly Claversal treatment resulted in the largest urinary excretion of 5-ASA and Ac-5-ASA (43.7% vs Asacol 35.6% and Pentasa 31.6%, median values of ingested daily dose).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,35.6,144708,DB00244,Mesalazine
,2129640,urinary excretion,"This can be explained by a larger systemic absorption of 5-ASA from Claversal, and accordingly Claversal treatment resulted in the largest urinary excretion of 5-ASA and Ac-5-ASA (43.7% vs Asacol 35.6% and Pentasa 31.6%, median values of ingested daily dose).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,31.6,144709,DB00244,Mesalazine
,10875540,time of defecation,"With formulation I there was a correlation between time of defecation before dosing and the type of absorption, monophasic and biphasic absorbers showed a significant difference in the time of defecation, e.g. 9.7+/-5.6 h vs 18.8+/-11.9 h (P = 0.0218).",Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875540/),h,9.7,146135,DB00244,Mesalazine
,10875540,time of defecation,"With formulation I there was a correlation between time of defecation before dosing and the type of absorption, monophasic and biphasic absorbers showed a significant difference in the time of defecation, e.g. 9.7+/-5.6 h vs 18.8+/-11.9 h (P = 0.0218).",Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875540/),h,18.8,146136,DB00244,Mesalazine
,10875540,time of defecation,"The impact of time of defecation before dosing was non-significant with formulation II, 16.7+/-7.2 h vs 15.1+/-4.2 h (P = 0.67).",Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875540/),h,16.7,146137,DB00244,Mesalazine
,10875540,time of defecation,"The impact of time of defecation before dosing was non-significant with formulation II, 16.7+/-7.2 h vs 15.1+/-4.2 h (P = 0.67).",Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875540/),h,15.1,146138,DB00244,Mesalazine
,10875540,renal clearance,"The renal clearance of the metabolite acetylmesalazine was independent of the observed defecation patterns (300 mL min(-1), P > 0.8), stool composition, and type of absorption.",Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875540/),[ml] / [min],300,146139,DB00244,Mesalazine
,15472525,Maximum plasma concentration of mesalazine (Cmax),"Maximum plasma concentration of mesalazine (Cmax) was 1332 ng/mL (geometric mean, geometric coefficient of variation [CV]: 0.57), obtained 3.7 hours (tmax; CV: 0.31) after drug administration.",Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15472525/),[ng] / [ml],1332,153138,DB00244,Mesalazine
,15472525,tmax,"Maximum plasma concentration of mesalazine (Cmax) was 1332 ng/mL (geometric mean, geometric coefficient of variation [CV]: 0.57), obtained 3.7 hours (tmax; CV: 0.31) after drug administration.",Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15472525/),h,3.7,153139,DB00244,Mesalazine
,15472525,area under the plasma concentration-time curve (AUC(0-infinity) ),Systemic exposure as determined by area under the plasma concentration-time curve (AUC(0-infinity) ) was 8712 ng/ml*h (CV: 0.44).,Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15472525/),[ng] / [h·ml],8712,153140,DB00244,Mesalazine
,15472525,Terminal half-life of elimination,Terminal half-life of elimination of mesalazine was 3.5 hours (t(1/2); CV: 1.43).,Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15472525/),h,3.5,153141,DB00244,Mesalazine
,16393291,relative percentage of,The relative percentage of 5-ASA absorption was more pronounced in the ascending colon (41 +/- 27.4%) than the ileo-caecal region (6.6 +/- 9.2%).,5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16393291/),%,41,165593,DB00244,Mesalazine
,16393291,relative percentage of,The relative percentage of 5-ASA absorption was more pronounced in the ascending colon (41 +/- 27.4%) than the ileo-caecal region (6.6 +/- 9.2%).,5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16393291/),%,6.6,165594,DB00244,Mesalazine
less,10976656,maximal plasma concentrations,"Most studies report maximal plasma concentrations of less than 1 mg/L after oral administration of slow release mesalazine, much lower than those observed after uncoated mesalazine but generally higher than after azo-bound drugs such as sulfasalazine.",Clinical pharmacokinetics of slow release mesalazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976656/),[mg] / [l],1,175041,DB00244,Mesalazine
,10976656,steady-state concentrations,Mean steady-state concentrations of 25.7+/-2.2 microg/kg wet weight are found in ileocolonic biopsy specimens from patients with irritable bowel syndrome treated for 1 week with slow release mesalazine 1.5 g/day.,Clinical pharmacokinetics of slow release mesalazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976656/),[μg] / [kg·weight·wet],25.7,175042,DB00244,Mesalazine
,26606108,m,The multiple reaction monitoring (MRM) mode of the negative ion was performed and the transitions of m/z 208.1→107.0 and m/z 211.1→110.1 were used to measure the derivative of mesalazine and mesalazine-d3.,"Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),,208.1,177631,DB00244,Mesalazine
,26606108,Nominal retention times,"Nominal retention times of mesalazine and IS were 3.08 and 3.07min, respectively.","Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),min,3.08,177632,DB00244,Mesalazine
,26606108,Nominal retention times,"Nominal retention times of mesalazine and IS were 3.08 and 3.07min, respectively.","Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),min,3.07,177633,DB00244,Mesalazine
,26606108,Absolute recovery,Absolute recovery was found to be between 82-95% for analyte and about 78% for IS.,"Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),%,82-95,177634,DB00244,Mesalazine
,26606108,Absolute recovery,Absolute recovery was found to be between 82-95% for analyte and about 78% for IS.,"Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),%,78,177635,DB00244,Mesalazine
,12752352,relative bioavailability,"The relative bioavailability of mesalazine was 92% comparing micropellets with Claversal tablets, and the cumulative urine excretion was c. 26% for both preparations, suggesting comparable systemic exposure for the two types of preparation.",Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752352/),%,92,180808,DB00244,Mesalazine
,12752352,cumulative urine excretion,"The relative bioavailability of mesalazine was 92% comparing micropellets with Claversal tablets, and the cumulative urine excretion was c. 26% for both preparations, suggesting comparable systemic exposure for the two types of preparation.",Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752352/),%,c. 26,180809,DB00244,Mesalazine
,16181300,ribonucleotide/tioguanine ratio,Mean 6-methylmercaptopurine ribonucleotide/tioguanine ratio increased significantly from 6.3 at baseline to 11.2.,The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16181300/),,6.3,184215,DB00244,Mesalazine
,16181300,ribonucleotide/tioguanine ratio,Mean 6-methylmercaptopurine ribonucleotide/tioguanine ratio increased significantly from 6.3 at baseline to 11.2.,The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16181300/),,11.2,184216,DB00244,Mesalazine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],11.1,185244,DB00244,Mesalazine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],12.0,185245,DB00244,Mesalazine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],27.7,185246,DB00244,Mesalazine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],30.5,185247,DB00244,Mesalazine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],3.45,185248,DB00244,Mesalazine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],2.36,185249,DB00244,Mesalazine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],21.3,185250,DB00244,Mesalazine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],18.0,185251,DB00244,Mesalazine
greater,7904547,elimination half-lives,Both drugs have reported elimination half-lives of greater than 1 month.,Clinical pharmacokinetics of slow-acting antirheumatic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904547/),month,1,193639,DB00244,Mesalazine
,11853180,maximum concentration (Cmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,2.5,194755,DB00244,Mesalazine
,11853180,maximum concentration (Cmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,0.5,194756,DB00244,Mesalazine
,11853180,time to Cmax (Tmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,5,194757,DB00244,Mesalazine
,11853180,time to Cmax (Tmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,12,194758,DB00244,Mesalazine
,11853180,Cmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,5.8,194759,DB00244,Mesalazine
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,13.3,194760,DB00244,Mesalazine
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,1,194761,DB00244,Mesalazine
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,7,194762,DB00244,Mesalazine
,11853180,area under the serum concentration-time curve (AUC),"The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h).",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h·μM,27.4,194763,DB00244,Mesalazine
,11853180,area under the serum concentration-time curve (AUC),"The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h).",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h·μM,29.4,194764,DB00244,Mesalazine
,11853180,percentage of urinary recovery,The percentage of urinary recovery of SASP 24 h after administration of the SASP suppository was approximately 0.2%.,Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),%,0.2,194765,DB00244,Mesalazine
more,11853180,urinary recovery,"On the other hand, approximately 0.3% of 5-ASA was recovered in the urine in unchanged form after the administration of the 5-ASA enema, whereas the urinary recovery of Ac-5-ASA was more than 10%.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),%,10,194766,DB00244,Mesalazine
,2369807,elimination half-life,"The elimination half-life of 5-ASA was 51.9 minutes, whereas the acetyl 5-ASA half-life could not be determined.",Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369807/),min,51.9,195222,DB00244,Mesalazine
,2369807,systemic relative bioavailability,"Food coadministration reduced 5-ASA and acetyl 5-ASA systemic relative bioavailability to 44% and 76%, respectively, compared with the fasting treatment.",Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369807/),%,44,195223,DB00244,Mesalazine
,2369807,systemic relative bioavailability,"Food coadministration reduced 5-ASA and acetyl 5-ASA systemic relative bioavailability to 44% and 76%, respectively, compared with the fasting treatment.",Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369807/),%,76,195224,DB00244,Mesalazine
,2518847,urinary recovery,Median urinary recovery values were 21.7% for Salazopyrin and 35.5% for Mesasal (fasting) (P less than 0.01).,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,21.7,203986,DB00244,Mesalazine
,2518847,urinary recovery,Median urinary recovery values were 21.7% for Salazopyrin and 35.5% for Mesasal (fasting) (P less than 0.01).,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,35.5,203987,DB00244,Mesalazine
,2518847,total faecal recovery,"The total faecal recovery values were 38.3 and 26.5%, respectively (NS).",Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,38.3,203988,DB00244,Mesalazine
,2518847,total faecal recovery,"The total faecal recovery values were 38.3 and 26.5%, respectively (NS).",Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,26.5,203989,DB00244,Mesalazine
,2518847,urinary recovery,Suppository administration of 5-ASA resulted in a low median urinary recovery of 10.8%.,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,10.8,203990,DB00244,Mesalazine
,1853156,peak plasma concentration,"The median peak plasma concentration of 5-ASA was 0.92 (range, 0.59-1.87) micrograms/ml at a median of 11 h after administration, and of Ac-5-ASA 1.62 (range, 1.03-4.36) micrograms/ml at a median of 12 h after administration.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],0.92,211865,DB00244,Mesalazine
,1853156,peak plasma concentration,"The median peak plasma concentration of 5-ASA was 0.92 (range, 0.59-1.87) micrograms/ml at a median of 11 h after administration, and of Ac-5-ASA 1.62 (range, 1.03-4.36) micrograms/ml at a median of 12 h after administration.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],1.62,211866,DB00244,Mesalazine
,1853156,plasma concentration,"At 24 h after administration the median plasma concentration for 5-ASA was 0.12 (range, 0-0.77) micrograms/ml and for Ac-5-ASA 0.36 (range, 0.01-1.6) micrograms/ml.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],0.12,211867,DB00244,Mesalazine
,1853156,plasma concentration,"At 24 h after administration the median plasma concentration for 5-ASA was 0.12 (range, 0-0.77) micrograms/ml and for Ac-5-ASA 0.36 (range, 0.01-1.6) micrograms/ml.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],0.36,211868,DB00244,Mesalazine
,1853156,urinary recovery,"Median urinary recovery during 45 h was 12.6% (range, 5.6-22.2%), indicating a low absorption at steady-state conditions.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),%,12.6,211869,DB00244,Mesalazine
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00244,Mesalazine
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00244,Mesalazine
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00244,Mesalazine
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00244,Mesalazine
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00244,Mesalazine
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00244,Mesalazine
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00244,Mesalazine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00244,Mesalazine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00244,Mesalazine
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00244,Mesalazine
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00244,Mesalazine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00244,Mesalazine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00244,Mesalazine
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00244,Mesalazine
,12130845,cumulative percentage release,"The in vitro studies in pH 6.8 phosphate buffer containing 2% w/v rat caecal contents showed that the cumulative percentage release of mesalazine after 26 h were 31.25+/-0.56, 46.25+/-0.96, 97.5+/-0.26 (mean+/-S.D.), respectively.",An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130845/),,31.25,215780,DB00244,Mesalazine
,12130845,cumulative percentage release,"The in vitro studies in pH 6.8 phosphate buffer containing 2% w/v rat caecal contents showed that the cumulative percentage release of mesalazine after 26 h were 31.25+/-0.56, 46.25+/-0.96, 97.5+/-0.26 (mean+/-S.D.), respectively.",An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130845/),,46.25,215781,DB00244,Mesalazine
,12130845,cumulative percentage release,"The in vitro studies in pH 6.8 phosphate buffer containing 2% w/v rat caecal contents showed that the cumulative percentage release of mesalazine after 26 h were 31.25+/-0.56, 46.25+/-0.96, 97.5+/-0.26 (mean+/-S.D.), respectively.",An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130845/),,97.5,215782,DB00244,Mesalazine
,12130845,bioavailability (AUC(0-->t*)),"The in vivo studies conducted in nine healthy male human volunteers for the various formulations revealed that, the drug release was initiated only after 5 h (i.e.) transit time of small intestine and the bioavailability (AUC(0-->t*)) of the drug was found to be 85.24+/-0.10, 196.08+/-0.12, 498.62+/-0.10 microg x h/ml 26 (mean+/-S.D.), respectively.",An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130845/),[h·μg] / [ml],85.24,215783,DB00244,Mesalazine
,12130845,bioavailability (AUC(0-->t*)),"The in vivo studies conducted in nine healthy male human volunteers for the various formulations revealed that, the drug release was initiated only after 5 h (i.e.) transit time of small intestine and the bioavailability (AUC(0-->t*)) of the drug was found to be 85.24+/-0.10, 196.08+/-0.12, 498.62+/-0.10 microg x h/ml 26 (mean+/-S.D.), respectively.",An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130845/),[h·μg] / [ml],196.08,215784,DB00244,Mesalazine
,12130845,bioavailability (AUC(0-->t*)),"The in vivo studies conducted in nine healthy male human volunteers for the various formulations revealed that, the drug release was initiated only after 5 h (i.e.) transit time of small intestine and the bioavailability (AUC(0-->t*)) of the drug was found to be 85.24+/-0.10, 196.08+/-0.12, 498.62+/-0.10 microg x h/ml 26 (mean+/-S.D.), respectively.",An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130845/),[h·μg] / [ml],498.62,215785,DB00244,Mesalazine
,32671846,urinary excretion,"Mean urinary excretion of 5-ASA plus N-Ac-5-ASA was comparable between treatments (dose A 21.3%, dose B 20.2%, dose C 17.9%).","Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671846/),%,21.3,222790,DB00244,Mesalazine
,32671846,urinary excretion,"Mean urinary excretion of 5-ASA plus N-Ac-5-ASA was comparable between treatments (dose A 21.3%, dose B 20.2%, dose C 17.9%).","Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671846/),%,20.2,222791,DB00244,Mesalazine
,32671846,urinary excretion,"Mean urinary excretion of 5-ASA plus N-Ac-5-ASA was comparable between treatments (dose A 21.3%, dose B 20.2%, dose C 17.9%).","Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671846/),%,17.9,222792,DB00244,Mesalazine
,27454774,elimination half-life,The elimination half-life of intravenously administered C2 was approximately 33 min.,Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),min,33,225325,DB00244,Mesalazine
,27454774,Cmax,"The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),[g] / [ml],2.5,225326,DB00244,Mesalazine
,27454774,AUCtot,"The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),[μg] / [min·ml],157,225327,DB00244,Mesalazine
,27454774,oral bioavailability,"The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),%,13,225328,DB00244,Mesalazine
,27454774,unbound fraction,"The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),%,89.,225329,DB00244,Mesalazine
,27454774,unbound fraction,"The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),%,92.,225330,DB00244,Mesalazine
,27454774,blood-plasma partitioning (BP ratio),"Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),,0.71,225331,DB00244,Mesalazine
,27454774,blood-plasma partitioning (BP ratio),"Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),,0.6,225332,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,11-33,228618,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,22,228619,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,14-31,228620,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,16-27,228621,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,12-35,228622,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,20,228623,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,10-35,228624,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,18-40,228625,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,15-53,228626,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,23-34,228627,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,27-56,228628,DB00244,Mesalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,31-44,228629,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,23-75,228630,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,38,228631,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,47-50,228632,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,17-36,228633,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,46,228634,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,22,228635,DB00244,Mesalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,37-44,228636,DB00244,Mesalazine
,3319458,steady state plasma levels,Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 microgram/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 micrograms/ml).,Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[μg] / [ml],0.02 to 1.2,232245,DB00244,Mesalazine
,3319458,steady state plasma levels,Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 microgram/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 micrograms/ml).,Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[μg] / [ml],0.1 to 2.9,232246,DB00244,Mesalazine
,3319458,t1/2,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),h,0.4 to 2.4,232247,DB00244,Mesalazine
,3319458,t1/2,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),h,6 to 9,232248,DB00244,Mesalazine
,3319458,renal clearance,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[ml] / [min],200 to 300,232249,DB00244,Mesalazine
,15586374,Limits' of detection,"Limits' of detection were 5 ng/mL for 5-ASA and 10 ng/mL for acetyl-5-ASA, respectively.",A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15586374/),[ng] / [ml],5,236457,DB00244,Mesalazine
,15586374,Limits' of detection,"Limits' of detection were 5 ng/mL for 5-ASA and 10 ng/mL for acetyl-5-ASA, respectively.",A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15586374/),[ng] / [ml],10,236458,DB00244,Mesalazine
,12492737,half-life,"After a single dose to patients, mean mesalazine half-life (s.d.) was 5.0 (3.6) h.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),h,5.0,240741,DB00244,Mesalazine
,12492737,C(min),"At steady-state, means (s.d.) were 89.1 (78.9) ng/mL for C(min), 361.1 (240.8) ng/mL for C(max), and 7.1 (7.3) h for half-life.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),[ng] / [ml],89.1,240742,DB00244,Mesalazine
,12492737,C(max),"At steady-state, means (s.d.) were 89.1 (78.9) ng/mL for C(min), 361.1 (240.8) ng/mL for C(max), and 7.1 (7.3) h for half-life.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),[ng] / [ml],361.1,240743,DB00244,Mesalazine
,12492737,half-life,"At steady-state, means (s.d.) were 89.1 (78.9) ng/mL for C(min), 361.1 (240.8) ng/mL for C(max), and 7.1 (7.3) h for half-life.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),h,7.1,240744,DB00244,Mesalazine
,12492737,concentrations,Mean (range) rectal mesalazine concentrations were 167 (1.4-541.6) ng/mg tissue.,"Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),ng,167,240745,DB00244,Mesalazine
,12492737,half-life,"After a single dose in healthy volunteers, mean (s.d.) half-life was 4.0 (4.7) h.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),h,4.0,240746,DB00244,Mesalazine
,12492737,C(min),"At steady-state, means (s.d.) were 22.4 (61.6) ng/mL for C(min), 359.4 (166.3) ng/mL for C(max), and 0.9 (0.5) h for half-life.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),[ng] / [ml],22.4,240747,DB00244,Mesalazine
,12492737,C(max),"At steady-state, means (s.d.) were 22.4 (61.6) ng/mL for C(min), 359.4 (166.3) ng/mL for C(max), and 0.9 (0.5) h for half-life.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),[ng] / [ml],359.4,240748,DB00244,Mesalazine
,12492737,half-life,"At steady-state, means (s.d.) were 22.4 (61.6) ng/mL for C(min), 359.4 (166.3) ng/mL for C(max), and 0.9 (0.5) h for half-life.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),h,0.9,240749,DB00244,Mesalazine
,12492737,bioavailability,"Mesalazine is released in the rectum of patients, with a bioavailability of about 40%.","Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492737/),%,40,240750,DB00244,Mesalazine
,2295273,peak plasma concentration,The mean peak plasma concentration of N-ac-5-ASA was 1.11 micrograms/ml in Group 1 subjects compared with 2.80 micrograms/ml in Group II subjects (P = N.S.).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),[μg] / [ml],1.11,244957,DB00244,Mesalazine
,2295273,peak plasma concentration,The mean peak plasma concentration of N-ac-5-ASA was 1.11 micrograms/ml in Group 1 subjects compared with 2.80 micrograms/ml in Group II subjects (P = N.S.).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),[μg] / [ml],2.80,244958,DB00244,Mesalazine
,2295273,recovery,The mean recovery of 5-ASA and N-ac-5-ASA in urine was 8.5 percent in Group I and 35.6 percent in Group II subjects (P less than 0.001).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),%,8.5,244959,DB00244,Mesalazine
,2295273,recovery,The mean recovery of 5-ASA and N-ac-5-ASA in urine was 8.5 percent in Group I and 35.6 percent in Group II subjects (P less than 0.001).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),%,35.6,244960,DB00244,Mesalazine
,12562452,Cmax,Mean Cmax values (350.6 +/- 322.6 ng/mL) were observed during location in the ileo-caecal region.,Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562452/),[ng] / [ml],350.6,248892,DB00244,Mesalazine
,12562452,relative absorption,The mean relative absorption of 5-ASA was 19.9 +/- 18.2% in the small intestine and ileum and 80.1 +/- 18.2% in the colon.,Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562452/),%,19.9,248893,DB00244,Mesalazine
,12562452,relative absorption,The mean relative absorption of 5-ASA was 19.9 +/- 18.2% in the small intestine and ileum and 80.1 +/- 18.2% in the colon.,Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562452/),%,80.1,248894,DB00244,Mesalazine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),[mg] / [l],0.09 to 1.16,251320,DB00244,Mesalazine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),pM,133-1733,251321,DB00244,Mesalazine
,24925268,flow rate,The flow rate was set at 1.0 mL/min with a split ratio of 3:2.,Development and validation of an LC-MS/MS method for the determination of mesalazine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24925268/),[ml] / [min],1.0,253542,DB00244,Mesalazine
,10719917,lower limit of detection,The lower limit of detection was 20 ng/ml in plasma and urine.,Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719917/),[ng] / [ml],20,265613,DB00244,Mesalazine
>,7741789,LD50,5-ASA sulfate can be considered as a non-toxic agent after single oral intake in rats (14-day LD50 > 6000 mg/kg b.w.).,Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741789/),[mg] / [kg],6000,266725,DB00244,Mesalazine
,7741789,excretion,"After a single oral administration of 1800 mg 5-ASA sulfate to 5 healthy human test subjects, 5-ASA sulfate was almost completely metabolized by all test subjects within 3 days; mean urinary and faecal excretion of unchanged 5-ASA sulfate amounted to only 6.7% of the administered dose.",Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741789/),%,6.,266726,DB00244,Mesalazine
,7848362,half-life,"In faecal suspensions, the half-life of the metabolic conversion of benzalazine was determined as 15 min and the formation of the metabolite 5-aminosalicylic acid (5-ASA) was demonstrated qualitatively.",Pharmacokinetic studies of benzalazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848362/),min,15,272381,DB00244,Mesalazine
